Clinical Trials

NCT05176483 | RECRUITING | PHASE1
1394 participants

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2021-12-14
Completion:
2027-01-31
Conditions
  • Renal Cell Carcinoma (RCC)
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Urothelial Carcinoma (UC)
  • Solid Tumor
  • Hepatocellular Carcinoma (HCC)
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)
  • Drug-Drug Interaction (DDI)
Interventions
  • DRUG
No Results Yet
NCT04999761 | RECRUITING | PHASE1
917 participants

AB122 Platform Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2021-06-01
Completion:
2027-06-30
Conditions
  • Advanced or Metastatic Solid Tumor
  • Pancreatic Ductal Adenocarcinoma
  • Colorectal Cancer
  • Non-small Cell Lung Cancer
  • Gastric Cancer
  • Alveolar Soft Part Sarcoma
  • Esophageal Cancer
  • Head and Neck Cancer
  • Biliary Tract Cancer
Interventions
  • DRUG
No Results Yet
NCT04929041 | SUSPENDED | PHASE2/PHASE3
427 participants

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2022-10-07
Completion:
2030-12-12
Conditions
  • Lung Adenocarcinoma
  • Lung Adenosquamous Carcinoma
  • Lung Non-Small Cell Carcinoma
  • Stage IIIB Lung Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
  • RADIATION
No Results Yet
NCT04900623 | RECRUITING | PHASE2
145 participants

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2021-07-02
Completion:
2030-06-01
Conditions
  • HPV-Associated Oropharyngeal Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage
  • HPV-Related Squamous Cell Carcinoma
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage
Interventions
  • DEVICE
  • RADIATION
  • DRUG
No Results Yet
NCT04803201 | SUSPENDED | PHASE2
170 participants

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-05
Start Date:
2021-10-08
Completion:
2027-05-19
Conditions
  • Angioimmunoblastic T-cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Follicular T-Cell Lymphoma
  • Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  • Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
  • Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page